NEW cancer treatments have been approved for use by the NHS in Scotland – including the first licensed treatment for a rare eye cancer that offers patients a “survival benefit”.
The Scottish Medicines Consortium (SMC) backed the use of the drug tebentafusp – also known as Kimmtrak – for patients with advanced uveal melanoma, a rare type of cancer of the eye.